Vimarsana
Biggest News Aggregation in the World

Page 7 - Axovant Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Axovant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Axovant Sciences Today - Breaking & Trending Today

Alzheimer's Therapeutics Market | AbbVie Inc. Teva Pharmaceuticals Ltd., Eisai Co. Ltd., Janssen Pharmaceuticals Inc. | By 2032 - Vimarsana News

Alzheimer's Therapeutics Market | AbbVie Inc. Teva Pharmaceuticals Ltd., Eisai Co. Ltd., Janssen Pharmaceuticals Inc. | By 2032

The global Alzheimer’s Therapeutics Market growth is anticipated to reach US$ 2.8 billion in 2022 and grow at a CAGR of 9.3% to US$ 6.8 billion by 2032. In 2021, Donepezil will hold the top spot in the global medication market with a share of 68.4%, according to a recent analysis by Future Market Insights.Alzheimer’...

Alzheimer's therapeutics market to reach $6.8 billion by 2032 - Vimarsana News

Alzheimer's therapeutics market to reach $6.8 billion by 2032

A large patient population is expected to expand the Alzheimer’s therapeutics market at a CAGR of 9.3 percent, suggested a report.

"Anti ESG" Investor Vivek Ramaswamy's New ETF: Top 10 Stock Picks - Vimarsana News

"Anti ESG" Investor Vivek Ramaswamy's New ETF: Top 10 Stock Picks

In this article, we will look at the top 10 stocks that make up anti-ESG investor Vivek Ramaswamy's new energy ETF.

Axovant: Fiscal Q1 Earnings Snapshot - Vimarsana News

Axovant: Fiscal Q1 Earnings Snapshot

NEW YORK (AP) _ Axovant Sciences Ltd. (SIOX) on Thursday reported a loss of $8.4 million in its fiscal first quarter. On a per-share basis, the New York-based company said it had a loss of 11 cents.

Source: apnews.com
Alzheimers Disease Therapeutics and Diagnostics Market: Population aging across the globe is a major factor driving the market - Vimarsana News

Alzheimers Disease Therapeutics and Diagnostics Market: Population aging across the globe is a major factor driving the market

Alzheimer’s disease is the most common reason of progressive dementia in the elderly population. There has been an exponential rise in the number of cases of Alzheimer’s disease worldwide emphasizing the necessity for developing an effective treatment.